Caesar I - Search Results

1

Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group.

Bregenzer N, Caesar I, Andus T, Hämling J, Malchow H, Schreiber S, Schölmerich J. Bregenzer N, et al. Among authors: caesar i. Z Gastroenterol. 1999 Oct;37(10):999-1004. Z Gastroenterol. 1999. PMID: 10549094 Clinical Trial.

2

Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.

Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Schölmerich J. Caesar I, et al. Z Gastroenterol. 1995 May;33(5):247-50. Z Gastroenterol. 1995. PMID: 7610691

3

[Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide].

Caesar I, Gross V, Roth M, Andus T, Hohenberger W, Schölmerich J. Caesar I, et al. Med Klin (Munich). 1997 Jun 15;92(6):358-62. doi: 10.1007/BF03044778. Med Klin (Munich). 1997. PMID: 9297069 German.

4

Evidence for continuous stimulation of interleukin-6 production in Crohn's disease.

Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Gross V, et al. Among authors: caesar i. Gastroenterology. 1992 Feb;102(2):514-9. doi: 10.1016/0016-5085(92)90098-j. Gastroenterology. 1992. PMID: 1370661

5

Focal white-matter lesions in brain of patients with inflammatory bowel disease.

Geissler A, Andus T, Roth M, Kullmann F, Caesar I, Held P, Gross V, Feuerbach S, Schölmerich J. Geissler A, et al. Among authors: caesar i. Lancet. 1995 Apr 8;345(8954):897-8. doi: 10.1016/s0140-6736(95)90013-6. Lancet. 1995. PMID: 7707814

6

PMN-elastase in assessment of patients with inflammatory bowel disease.

Andus T, Gross V, Caesar I, Krumm D, Hosp J, Gerok W, Schölmerich J. Andus T, et al. Among authors: caesar i. Dig Dis Sci. 1993 Sep;38(9):1638-44. doi: 10.1007/BF01303172. Dig Dis Sci. 1993. PMID: 8359075

7

Distinct patterns of immunoglobulin classes and IgG subclasses of autoantibodies in patients with inflammatory bowel disease.

Müller-Ladner U, Gross V, Andus T, Gschwendtner H, Roth M, Caesar I, Schölmerich J, Lang B. Müller-Ladner U, et al. Among authors: caesar i. Eur J Gastroenterol Hepatol. 1996 Jun;8(6):579-84. doi: 10.1097/00042737-199606000-00016. Eur J Gastroenterol Hepatol. 1996. PMID: 8823574

8

Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.

Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bär U, Weber A, Gierend M, Ewe K, Schölmerich J. Gross V, et al. Among authors: caesar i. Eur J Gastroenterol Hepatol. 1996 Sep;8(9):905-9. Eur J Gastroenterol Hepatol. 1996. PMID: 8889459 Clinical Trial.

9

Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.

Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Schölmerich J. Caesar I, et al. Hepatogastroenterology. 1997 Mar-Apr;44(14):445-51. Hepatogastroenterology. 1997. PMID: 9164517 Clinical Trial.

10

[Initial symptoms, extra-intestinal manifestations and course of pregnancy in chronic inflammatory bowel diseases].

Rath HC, Andus T, Caesar I, Schölmerich J. Rath HC, et al. Among authors: caesar i. Med Klin (Munich). 1998 Jul 15;93(7):395-400. doi: 10.1007/BF03042635. Med Klin (Munich). 1998. PMID: 9711052 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters